LifeVantage Corporation — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2016. Although the request metadata refers to “2015 Q4,” this filing covers FY2016 and includes quarterly results, including the quarter ended June 30, 2016. The report was filed December 12, 2016, after a delay related to an audit committee review.
Business context
LifeVantage sells dietary supplements and other wellness products through independent distributors and preferred customers. Its principal product lines include Protandim and TrueScience skin care. The United States generated about 74% of FY2016 revenue and Japan about 18%. The company reported approximately 69,000 active distributors and 117,000 active preferred customers at year-end.
Financial performance and liquidity
| Metric | FY2016 | FY2015 |
|---|---|---|
| Net revenue | $206.5 million | $190.3 million |
| Gross profit / margin | $172.6 million / 83.6% | $162.3 million / 85.3% |
| Operating income / margin | $13.4 million / 6.6% | $13.9 million / 7.4% |
| Net income | $6.0 million | $7.0 million |
| Diluted earnings per share | $0.41 | $0.49 |
| Operating cash flow | $6.0 million | $13.2 million |
| Cash at year-end | $7.9 million | $13.9 million |
| Working capital | $13.9 million | $4.6 million |
- Revenue increased 8.5%, driven principally by Americas growth, new product launches and more active distributors. Americas revenue rose 14.6% to $158.3 million; Asia/Pacific & Europe revenue fell 7.6% to $48.2 million. Japan sales declined 12.3%.
- Gross margin fell 1.7 percentage points, reflecting the absence of $2.0 million of product-recall insurance benefits recorded in FY2015, product mix, and higher shipping, storage and inventory testing costs. Commissions and incentives increased to 49.9% of revenue from 47.8%.
- Net income declined despite higher revenue, as operating income decreased and other expense increased. Other expense included interest expense, a $1.2 million write-off of capitalized software costs, and debt-refinancing costs.
- Operating cash flow declined mainly because inventory purchases used $15.7 million of cash. Inventory rose to $25.1 million from $9.2 million.
- At year-end, debt principal was $9.5 million. The March 2016 refinancing provided a $10 million term loan at a fixed 4.93% rate and a $2 million revolving facility; the term loan matures in March 2019 and is secured by substantially all assets. The company reported compliance with financial covenants at June 30, but later received a waiver extending the deadline to provide audited FY2016 statements to December 31, 2016.
- Fourth-quarter revenue was $53.0 million and net income was $2.35 million, versus $45.3 million and $0.23 million, respectively, in FY2015 Q4.
Material changes, outlook and risks
- The audit committee found that distributors had carried or shipped products primarily into four countries where products were unregistered or direct selling was restricted, and that residents of restricted markets had been allowed to enroll as distributors. The company estimated related revenue at $17.3 million in FY2016, compared with $6.7 million in FY2015.
- Management concluded that the related revenue was properly recognized, no associated tax or other accrual was necessary, and prior statements did not require restatement. The auditor gave an unqualified opinion on the FY2016 financial statements but an adverse opinion on internal control over financial reporting. Management also concluded disclosure controls were ineffective due to a material weakness in international policies, monitoring, training and controls. Remediation was underway; completion timing was not established.
- The company expects revenue in future periods from sales carried or shipped into the affected countries to be significantly lower. Management expected gross margin of 83%–85% for the foreseeable future and anticipated moderate growth in Asia/Pacific & Europe, while emphasizing regulatory compliance and market-specific sales efforts.
- Management estimated $2.5–$3.0 million in additional SG&A through the first two quarters of FY2017 for the audit committee review, with further internal-control remediation and operational expenses expected through approximately FY2017 year-end.
- A securities class action and shareholder derivative litigation followed allegations concerning FY2016 internal controls and financial reporting. The company stated it would defend the cases and recorded no loss accrual because liability was not considered probable or estimable. A former distributor’s defamation counterclaim also remained unresolved; the company had prevailed on the other claims in that case.
- Other notable risks include distributor retention and compliance, dependence on Protandim and TrueScience (77.9% of revenue combined), foreign exchange exposure, inventory obsolescence, third-party manufacturing, product regulation and claims, and debt covenants. The company’s U.S. dollar sensitivity analysis estimated that a 10% strengthening against relevant foreign currencies would reduce FY2016 revenue by $4.9 million.
Important facts for investors to verify
- Whether the international-sales control remediation is completed, tested and deemed effective, and whether subsequent reviews lead to adjustments or restatements.
- The actual revenue and earnings impact from restricting sales into the four affected countries, compared with management’s expectations.
- Inventory sell-through, aging and potential obsolescence following the increase to $25.1 million, and the resulting effect on cash flow and margins.
- Compliance with lender reporting requirements and financial covenants, including the outcome of the December 31, 2016 audited-statements deadline.
- Developments in the securities, derivative and distributor litigation, including potential costs, liabilities and effects on listing status or reputation.